Teva Pharmaceutical Industries (TEVA) Return on Equity (2016 - 2025)
Historic Return on Equity for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 0.21%.
- Teva Pharmaceutical Industries' Return on Equity rose 3900.0% to 0.21% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.21%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 0.21% for FY2025, which is 5000.0% up from last year.
- Teva Pharmaceutical Industries' Return on Equity amounted to 0.21% in Q4 2025, which was up 3900.0% from 0.09% recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Return on Equity high stood at 0.21% for Q4 2025, and its period low was 0.39% during Q3 2024.
- For the 5-year period, Teva Pharmaceutical Industries' Return on Equity averaged around 0.18%, with its median value being 0.22% (2023).
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Return on Equity plummeted by -3500bps in 2021, and later surged by 4900bps in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Return on Equity (Quarter) stood at 0.04% in 2021, then tumbled by -807bps to 0.28% in 2022, then tumbled by -33bps to 0.37% in 2023, then soared by 53bps to 0.17% in 2024, then skyrocketed by 223bps to 0.21% in 2025.
- Its last three reported values are 0.21% in Q4 2025, 0.09% for Q3 2025, and 0.03% during Q2 2025.